|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
CZ243498A3
(cs)
|
1996-02-14 |
1999-09-15 |
Isis Pharmaceuticals, Inc. |
Oligonukleotidy s mezerou a modifikovaným cukrem
|
|
US20030036516A1
(en)
*
|
1997-09-10 |
2003-02-20 |
Sudhir Agrawal |
Method for using oligonucleotides having modified cpg dinucleotides
|
|
AU3465599A
(en)
*
|
1998-04-01 |
1999-10-18 |
Hybridon, Inc. |
Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
|
|
US20040063618A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Muthiah Manoharan |
Peptide nucleic acids having improved uptake and tissue distribution
|
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US20030220486A1
(en)
*
|
1999-04-01 |
2003-11-27 |
Wen-Qiang Zhou |
Mixed backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
|
EP1537208A1
(en)
*
|
2002-09-13 |
2005-06-08 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
EP1601789A4
(en)
*
|
2003-01-16 |
2007-10-31 |
Idera Pharmaceuticals Inc |
MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS USING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
|
|
CA2526212C
(en)
*
|
2003-05-16 |
2013-08-27 |
Hybridon, Inc. |
Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
|
|
JP4874801B2
(ja)
|
2003-06-11 |
2012-02-15 |
イデラ ファーマシューティカルズ インコーポレイテッド |
安定化免疫調節オリゴヌクレオチド
|
|
US20060074040A1
(en)
|
2003-07-15 |
2006-04-06 |
Hybridon, Inc. |
Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
|
|
CA2549173A1
(en)
|
2003-12-08 |
2005-07-07 |
Hybridon, Inc. |
Modulation of immunostimulatory properties by small oligonucleotide-based compounds
|
|
EP1725266A4
(en)
*
|
2004-02-20 |
2008-05-07 |
Hybridon Inc |
POWERFUL MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES
|
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US7427405B2
(en)
*
|
2004-06-15 |
2008-09-23 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory oligonucleotide multimers
|
|
EP1765417A4
(en)
|
2004-06-15 |
2009-03-25 |
Idera Pharmaceuticals Inc |
MULTIMERS OF OLIGONUCLEOTIDES IMMUNOSTIMULATORS
|
|
US7923206B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
|
JP4981681B2
(ja)
|
2004-12-09 |
2012-07-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉rnaなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
|
|
WO2006117400A2
(en)
|
2005-05-05 |
2006-11-09 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
|
|
ATE476193T1
(de)
|
2005-07-01 |
2010-08-15 |
Index Pharmaceuticals Ab |
Immunstimulatorisches verfahren
|
|
SI2179737T1
(sl)
*
|
2005-07-01 |
2014-02-28 |
Index Pharmaceuticals Ab |
Modulacija reakcije na stereoide
|
|
EP1940472A1
(en)
*
|
2005-10-28 |
2008-07-09 |
Index Pharmaceuticals AB |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
|
WO2007055704A2
(en)
|
2005-11-07 |
2007-05-18 |
Idera Pharmaceuticals |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
US7776834B2
(en)
*
|
2005-11-07 |
2010-08-17 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
US7470674B2
(en)
*
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
US7786089B2
(en)
*
|
2005-12-20 |
2010-08-31 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
|
|
AU2006336242A1
(en)
*
|
2005-12-20 |
2007-07-26 |
Idera Pharmaceuticals, Inc. |
Novel synthetic agonists of toll-like receptors containing CG dinucleotide modifications
|
|
WO2008017473A2
(en)
|
2006-08-08 |
2008-02-14 |
Gunther Hartmann |
Structure and use of 5' phosphate oligonucleotides
|
|
EP2081949B1
(en)
|
2006-09-22 |
2014-12-10 |
GE Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
|
|
EP2338499A1
(en)
|
2006-10-10 |
2011-06-29 |
Gunther Hartmann |
5' triphosphate oligonucleotide induces anti-viral response
|
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
DK2470656T3
(da)
|
2009-08-27 |
2015-06-22 |
Idera Pharmaceuticals Inc |
Sammensætning til hæmning af genekspression og anvendelser heraf
|
|
US20120270930A1
(en)
|
2009-10-29 |
2012-10-25 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Methods and compositions for dysferlin exon-skipping
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
EP2453017A1
(en)
|
2010-11-12 |
2012-05-16 |
Antisense Pharma GmbH |
Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
|
|
US8877722B2
(en)
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
BR112014028644A2
(pt)
|
2012-05-16 |
2017-08-15 |
Rana Therapeutics Inc |
Composições e métodos para modulação da expressão de atp2a2
|
|
HK1208700A1
(en)
|
2012-05-16 |
2016-03-11 |
Rana Therapeutics Inc. |
Compositions and methods for modulating smn gene family expression
|
|
WO2014030066A2
(en)
|
2012-08-22 |
2014-02-27 |
Bernitz Mats Nilsson |
Methods for identifying nucleic acid sequences
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
KR20170072244A
(ko)
|
2014-10-10 |
2017-06-26 |
이데라 파마슈티칼즈, 인코포레이티드 |
관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
|
|
HK1256704A1
(zh)
|
2015-08-21 |
2019-10-04 |
辉瑞公司 |
包含治疗剂的治疗性纳米粒及其制备和使用方法
|
|
CN117337168A
(zh)
|
2021-04-01 |
2024-01-02 |
渤健马萨诸塞州股份有限公司 |
向中枢神经系统的核酸递送
|
|
WO2025088117A1
(en)
|
2023-10-25 |
2025-05-01 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
|
|
WO2025158069A1
(en)
|
2024-01-25 |
2025-07-31 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
|